EcoDrugPlus

Exportin 1

Ensembl ID : ENSHBUG00000007128
Gene Symbol: XPO1
3 Cross references
224 Possible Orthologues:

Farnesyl Diphosphate Synthase

Ensembl ID : ENSHBUG00000003690
Gene Symbol: FDPS
3 Cross references
267 Possible Orthologues:

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSHBUG00000000314
Gene Symbol: FDFT1
3 Cross references
220 Possible Orthologues:

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSHBUG00000001560
Gene Symbol: FNTA
3 Cross references
221 Possible Orthologues:

Female Protein-Like

Ensembl ID : ENSHBUG00000017058
Gene Symbol: LOC102289541
2 Cross references
386 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSHBUG00000019579
Gene Symbol: FGFR1
3 Cross references
204 Possible Orthologues:

Fibroblast Growth Factor Receptor 1-A-Like

Ensembl ID : ENSHBUG00000013450
Gene Symbol: LOC102289294
4 Cross references
205 Possible Orthologues:

Fibroblast Growth Factor Receptor 1-A-Like

Ensembl ID : ENSHBUG00000019510
Gene Symbol: LOC102292008
2 Cross references
155 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSHBUG00000010635
Gene Symbol: FGFR2
3 Cross references
214 Possible Orthologues:

Fibroblast Growth Factor Receptor 3-Like

Ensembl ID : ENSHBUG00000010008
Gene Symbol: LOC102291452
3 Cross references
193 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSHBUG00000018437
Gene Symbol: FLT1
3 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSHBUG00000011081
Gene Symbol: FLT4
3 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).